Fresh commentary from the team at Morgans has identified an exciting exploration-stage mining growth stock investors should be adding to their watchlist. 

The company in question is G50 Corp Ltd (ASX: G50). 

Company overview

G50 Corp was established to identify and advance opportunities involving economically viable precious metal deposits across the United States.

The Company’s flagship Golconda Project, situated in northwestern Arizona, represents its most advanced exploration asset. The project encompasses a number of historically worked, small-scale precious and polymetallic mines, positioned directly southeast of a significant porphyry copper-molybdenum system.

In central Nevada, Gold 50 holds the Spitfire, Broken Hills, Top Gun and Caisson Projects, each offering further exploration potential.

Despite limited modern exploration across these properties, all four projects exhibit evidence of gold mineralisation at surface. In particular, the Spitfire Project has recorded exceptionally high-grade, or “bonanza-grade,” gold and silver mineralisation.

As is typical with small-cap shares, it has experienced volatility in 2026. 

At the time of writing, its share price is down 35% year to date. 

For comparison, the S&P/ASX Small Ordinaries (ASX: XSO) index is down 8% in the same period, while the S&P/ASX 200 Index (ASX: XJO) is up 2%.

However, Morgans is bullish this exciting growth stock could be set to explode. 

Strong momentum

According to Morgans, G50 is making progress across its projects. 

Recent exploration has expanded the Golconda mineral system and identified high-grade gold at White Caps. 

The Company is also exploring ways to develop and potentially generate revenue from its gallium resources, which could benefit from growing demand for critical minerals.

G50 recently raised additional funding through a placement led by Hancock. 

This gives the Company the money it needs to increase exploration, develop its gallium opportunities and continue work on the larger Golconda project, including future funding and permitting requirements.

G50 continues to unlock value across its asset base, with recent activity extending the Golconda system, delivering a high-grade gold discovery at White Caps, and advancing potential gallium development pathways amid an increasingly supportive backdrop for critical minerals.

Big upside for this growth stock

Based on this guidance, Morgans has a $1.94 price target and speculative buy recommendation on G50 shares. 

From current levels, this indicates an upside of 321%. 

Following the recent Hancock-cornerstoned placement, the Company is well funded to accelerate exploration and advance potential gallium monetisation pathways, supporting early cash flow, financing and permitting for the broader Golconda deposit. We maintain our SPECULATIVE BUY rating with a target price of A$1.94ps.

The post Could this exciting growth stock be set to triple? Morgans thinks it can appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• The ASX 200 has dropped to a 3-day low. Here’s what’s happening
• Are NAB, ANZ, Westpac and CBA shares attractive buys right now?
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

June 3 would have been an excellent day to channel your inner Warren Buffett and buy CSL Ltd (ASX: CSL) shares.

Of the many investment quotes Buffett is famous for, perhaps the best known is, “Be greedy when others are fearful.”

Indeed, on 3 June, a lot of investors were fearful about buying the S&P/ASX 200 Index (ASX: XJO) biotech giant, after it closed at a more than nine-year low.

Why did CSL shares crash to a multi-year low?

The CSL share price decline began in mid-2024 and ran for roughly two years.

Over this time the company issued a number of earnings downgrades, partly driven by lower than forecast plasma demand.

Vaccine uptakes in the United States also slumped, right about when management announced their plan to spin off the CSL Seqirus segment, its influenza vaccine business, into a separate ASX-listed company. (That plan remains on hold at the moment.)

Investors also reacted negatively to former CSL CEO Paul McKenzie’s unexpected exit in February this year.

Which brings us back to the closing bell on June 3, when you could have picked up CSL for just $92.24 a share.

Investing $10,000 into the ASX 200 healthcare share

If you’d embraced your inner Warren Buffett and invested $10,000 in the ASX 200 biotech stock on 3 June, you could have picked up 108 shares with a bit of pocket money left over.

On Tuesday, CSL shares were trading for $171.66 apiece. And if you held the stock through to market close, you’d also have received the final CSL dividend of $2.277 a share.

The stock is trading ex-dividend today.

So, if we add that passive income payout back into the recent share price, then the accumulated value of the shares you picked up for $92.24 on June 3 works out to (a rounded) $173.94 each.

Meaning the 108 shares you acquired for $10,000 just over three months ago would be worth $18,786 today.

Or a gain of 87.9%.

What’s sent the CSL shares rocketing?

By 17 August, shares in the ASX 200 healthcare stock had recovered to $134.60 as investors began to bet on the success of the company’s ‘reset’ process.

Then on 18 August, CSL shares rocketed 17.3% following the release of the company’s full-year FY 2026 results.

While revenue declined 1% year on year and CSL reported a net loss after tax of US$2.6 billion, the company forecast steady revenue in FY 2027 and underlying NPAT growth of around 5%.

“FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth,” CSL interim CEO Gordon Naylor said on the day of the results release.

The post $10,000 invested in CSL shares in June is now worth… appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares. 3 ASX healthcare stocks with bigger upside
• If I invest $10,000 in CSL shares, what passive income will I earn in FY27?
• UBS names its 10 top ASX picks for the next 3-6 months
• Are CSL shares still cheap after almost doubling since June?
• CSL led the ASX healthcare shares rebound. Can it continue?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have surged 32% over the past month after stronger-than-expected plasma product sales. But with the rally potentially priced in, analysts see better value elsewhere in healthcare.

CSL shares are now trading around $174.80, above the average broker price target. Macquarie has a neutral rating and a target of just over $133, while UBS is more bullish at $181 and Morgan Stanley has a $172 target.

So, where could investors look instead?

Pro Medicus Ltd (ASX: PME)

Pro Medicus shares have endured a brutal 12 months, falling around 43%. But unlike CSL shares, the sell-off hasn’t been accompanied by a deterioration in the company’s underlying growth.

FY26 revenue increased 22.9% to $261.7 million, while underlying EBIT and NPAT climbed 24.4% and 24.1%, respectively.

Its Visage imaging software is already used by major healthcare systems across North America, yet management estimates it has captured only around 11% of the US market. That leaves plenty of room to grow.

Citi has a buy rating and $225 target, implying around 33% upside. Bell Potter is also bullish, with a $226 target, while Barrenjoey has a $210 target. JPMorgan is more cautious with a hold rating and $211 target.

ResMed Inc (ASX: RMD)

ResMed shares have bounced around 25% from their multi-year low in June, but remain down roughly 25% over 12 months. That’s a steeper decline than CSL shares, which still fell 18% over the same period despite their recent rebound.

The sell-off reflected broader pressure on healthcare shares, alongside macroeconomic uncertainty, inflation and cost-of-living concerns. A soft third-quarter update in May added to the pressure.

However, ResMed subsequently delivered a stronger fourth-quarter result, helping restore investor confidence.

The sleep-disorder specialist continues to deliver healthy revenue growth, expanding margins and strong free cash flow. Its third-quarter revenue rose 11% to US$1.4 billion, driven by demand for sleep devices, masks and accessories.

Most brokers rate ResMed shares buy or strong buy. The highest price target of $45.90 implies potential upside of around 46%.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals operates in a highly specialised healthcare niche: radiopharmaceuticals. Its products combine radioactive isotopes with targeted diagnostics and therapies, helping doctors detect and treat diseases such as cancer with greater precision.

That creates significant barriers to entry and gives Telix shares an interesting growth profile that differs from CSL shares.

In August, Telix reported a 22% year-on-year increase in revenue to US$477 million, putting it towards the upper end of its FY26 guidance.

Brokers are increasingly bullish, with 13 of 16 analysts rating Telix shares buy or strong buy. The average $25.29 target implies roughly 53% upside from $16.50, while the most bullish forecast points to more than 85% potential upside.

For investors looking beyond CSL shares, these three healthcare names could offer considerably more upside.

The post Forget CSL shares. 3 ASX healthcare stocks with bigger upside appeared first on The Motley Fool Australia.

More reading

• $10,000 invested in CSL shares in June is now worth…
• 6 ASX shares tipped by brokers to rise 34% to 87%
• If I invest $10,000 in CSL shares, what passive income will I earn in FY27?
• UBS names its 10 top ASX picks for the next 3-6 months
• Are CSL shares still cheap after almost doubling since June?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Pro Medicus, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.